Thermo Fisher Scientific Inc.

Thermo Fisher's consumable-and-services model creates strong repeat-purchase dynamics across pharmaceutical, biotechnology, and academic customers, with reagent and supply orders placed on recurring quarterly or monthly cycles. Multi-year biopharma services contracts provide additional forward visibility, though the post-COVID demand normalization in FY2023 illustrates sensitivity to funding cycles.

Four segments serve distinct end markets: Laboratory Products and Biopharma Services (54% of FY2025 revenue at $23.98B), Life Sciences Solutions (23% at $10.37B), Analytical Instruments (17% at $7.55B), and Specialty Diagnostics (10.5% at $4.68B). The leading segment at 54% is itself a broad collection of consumables, equipment, chemicals, and outsourced services rather than a single product line, limiting concentration risk within it.

The United States represented 52% of FY2024 revenue ($22.5B of $42.9B total), with Europe at 25% and Asia-Pacific at 18.5%. China, estimated at roughly 8% of sales, declined mid-single digits in FY2025 and represents a recurring drag since FY2023, while other markets are immaterial.

Adjusted operating margin held at 22.7% in FY2025 versus 22.6% in FY2024, reflecting a stable mix of high-margin instruments and reagents offset by the lower-margin laboratory distribution business that comprises the majority of the company's largest segment. Operating leverage exists within the instruments and life sciences divisions but is meaningfully diluted by the scale of distribution.

Reagents and consumables consumed in pharmaceutical QA/QC, clinical trials, and laboratory research are mission-critical repeat purchases with minimal discretionary character, and biopharma services contracts provide multi-year contractual revenue. Laboratory distribution, which accounts for a large share of total revenue, introduces a more transactional, lower-margin component that tempers the overall revenue quality profile.